russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLCrussjcardiol-2147Research ArticleКЛИНИКА И ФАРМАЦИЯCLINIC AND PHARMACOLOGYЗНАЧЕНИЕ ИСХОДНОГО УРОВНЯ АКТИВНОСТИ АНГИОТЕНЗИН- ПРЕВРАЩАЮЩЕГО ФЕРМЕНТА У БОЛЬНЫХ С МЕТАБОЛИЧЕСКИМ СИНДРОМОМ ПРИ НАЗНАЧЕНИИ ИНГИБИТОРОВ АПФ И АГОНИСТОВ ИМИДАЗОЛИНОВЫХ РЕЦЕПТОРОВSIGNIFICANCE OF BASELINE ACE ACTIVITY IN PATIENTS WITH METABOLIC SYNDROME WHEN ADMINISTRATION OF ACE INHIBITORS AND IMIDAZOLINE AGONISTS IS CONSIDEREDАпаринаТ. В.AparinaT. V.БритовА. Н.BritovA. N.ДилакянЭ. А.DilakyanE. A.МетельскаяВ. А.MetelskayaV. A.ГомазковО. А.GomazkovO. A.Государственный научно-исследовательский центр профилактической медицины МЗРФ, НИИ биомедицинской химии РАМН, МоскваRussian Federation200128042001023237Copyright © Апарина Т.В., Бритов А.Н., Дилакян Э.А., Метельская В.А., Гомазков О.А., 20012001Апарина Т.В., Бритов А.Н., Дилакян Э.А., Метельская В.А., Гомазков О.А.Aparina T.V., Britov A.N., Dilakyan E.A., Metelskaya V.A., Gomazkov O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/2147

Значение исходного уровня активности ангиотензин-превращающего фермента у больных сметаболическим синдромом при назначении ингибиторов АПФ и агонистов имидазолиновых рецепторов.

Significance of baseline ACE activity in patients with metabolic syndrome when administration of ACE inhibitors and imidazoline agonists is considered.

ReferencesMogensen C.E., Hansen K.W. Preventing and postponing renal disease in insulin-dependent diabetes by glycemic and non- glycemic intervention. // Contrib Nephrol 1990; 78: 73-100.Mogensen C.E., Hansen K.W. Preventing and postponing renal disease in insulin-dependent diabetes by glycemic and non- glycemic intervention. // Contrib Nephrol 1990; 78: 73-100.Gall M.A., Passing P., Skott P., et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulindependent) diabetic patients. // Diabetologia 1991; 34:655-661.Gall M.A., Passing P., Skott P., et al. Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulindependent) diabetic patients. // Diabetologia 1991; 34:655-661.Ritz E., Hasslacher C, Mann J., Guo Ji-Zhen. Hypertension and vascular disease as complications of diabetes. // J.Hypertension 1997; 7:233-240Ritz E., Hasslacher C, Mann J., Guo Ji-Zhen. Hypertension and vascular disease as complications of diabetes. // J.Hypertension 1997; 7:233-240Reaven GM. Role of insulin in human disease. // Diabetes 1988; 37: 1595-1607.Reaven GM. Role of insulin in human disease. // Diabetes 1988; 37: 1595-1607.Ю.В. Зимин. Артериальная гипертония при сахарном диабете: особенности патогенеза и лечения. // Кардиология 1997;11:81-90.Ю.В. Зимин. Артериальная гипертония при сахарном диабете: особенности патогенеза и лечения. // Кардиология 1997;11:81-90.Н. Laragh, B.M. Brenner. J. Hypertension: pathophysiology, diagnosis and treatment. New York: Raven Press 1990; 1703-1715Н. Laragh, B.M. Brenner. J. Hypertension: pathophysiology, diagnosis and treatment. New York: Raven Press 1990; 1703-1715Isfan NW, Plaisted CS, Bistrian BR, Blakburn GL. Insulin resistance versus insulin secretion in hypertension of obesity. // J. Hypertension 1992; 19: 385-392.Isfan NW, Plaisted CS, Bistrian BR, Blakburn GL. Insulin resistance versus insulin secretion in hypertension of obesity. // J. Hypertension 1992; 19: 385-392.Ferrannini, Andrea N. Insulin Resistance, Hyperinsulinernia and Blood pressure. // J. Hypertension 1997; 30(5):1144-1149.Ferrannini, Andrea N. Insulin Resistance, Hyperinsulinernia and Blood pressure. // J. Hypertension 1997; 30(5):1144-1149.Caro J.F. Insulin resistance in obese and nonobese man. //J.Clinical Endocrinology Metabolism 1991; 73: 691-695.Caro J.F. Insulin resistance in obese and nonobese man. //J.Clinical Endocrinology Metabolism 1991; 73: 691-695.W.Ferrannmi E, Buzzigoli G, Bonnadonna R, et al. Insulin resistance in essential hypertension. // N.Engl.J.Med. l987; 317: 350-357.W.Ferrannmi E, Buzzigoli G, Bonnadonna R, et al. Insulin resistance in essential hypertension. // N.Engl.J.Med. l987; 317: 350-357.Lithell H. Effect of antihypertensive drugs in insulin, glucose and lipid metabolism. // Diabetes Care 1991; 14: 203-209.Lithell H. Effect of antihypertensive drugs in insulin, glucose and lipid metabolism. // Diabetes Care 1991; 14: 203-209.Weinberger ME. Antihypertensive therapy and lipids. Evidence, mechanisms and implications. // Arch.Intern.Med. 1985;145:1103-1105.Weinberger ME. Antihypertensive therapy and lipids. Evidence, mechanisms and implications. // Arch.Intern.Med. 1985;145:1103-1105.Cutler R. Effects of antihypertensive therapy on lipid metabolism.// Am. J. Cardiol 1983; 51:628-631.Cutler R. Effects of antihypertensive therapy on lipid metabolism.// Am. J. Cardiol 1983; 51:628-631.Kaplan NM. Problems with the use of diuretics in the treatment of hypertension. // Am. J. Nefrol. 1986; 6:1-5.Kaplan NM. Problems with the use of diuretics in the treatment of hypertension. // Am. J. Nefrol. 1986; 6:1-5.KnochelJ. Diuretoc-induced hypokalemia.//Am.J.Med. 1984;77:18-27.KnochelJ. Diuretoc-induced hypokalemia.//Am.J.Med. 1984;77:18-27.Te-Chao F., Wann-Chu H. Role of angiotensin II in Hyperinsulinemia-induced hypertension in rats. // J. Hypertension 1998; 16(2,Part 1): 1767-1771.Te-Chao F., Wann-Chu H. Role of angiotensin II in Hyperinsulinemia-induced hypertension in rats. // J. Hypertension 1998; 16(2,Part 1): 1767-1771.Lender D, Arauz-Pacheco C, Breen L, et al: A Double Blind Comparison of the Effects of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. // Am. J. Hypertension 1999; 12:298-303.Lender D, Arauz-Pacheco C, Breen L, et al: A Double Blind Comparison of the Effects of Amlodipin and Enalapril on Insulin Sensitivity in Hypertensive Patients. // Am. J. Hypertension 1999; 12:298-303.Takezako T, Saku K, Zhang B, et al. Angiotensin I Converting Enzyme Gene Polymorphism and Insulin Resistance in Patients with Angina Pectoris. // American J. Hypertension 1999; 12:291-297.Takezako T, Saku K, Zhang B, et al. Angiotensin I Converting Enzyme Gene Polymorphism and Insulin Resistance in Patients with Angina Pectoris. // American J. Hypertension 1999; 12:291-297.MJA Saad, Univ Estadual Campinas. Effect of captopril, losartan and bradykinin on early steps of insulin action. // Diabetes 1997; 46(12):1950-1957.MJA Saad, Univ Estadual Campinas. Effect of captopril, losartan and bradykinin on early steps of insulin action. // Diabetes 1997; 46(12):1950-1957.Henriksen et al. Imidazoline Receptors and Muscle Glucose Transport. // J.Hypertension 1997;30(6):1559-1567.Henriksen et al. Imidazoline Receptors and Muscle Glucose Transport. // J.Hypertension 1997;30(6):1559-1567.Bousquet P, Dontenwill M, Greney H, et al. Imidazoline receptors: an update. // J. Hypertension 1998;16(Suppl 3):S1-S5.Bousquet P, Dontenwill M, Greney H, et al. Imidazoline receptors: an update. // J. Hypertension 1998;16(Suppl 3):S1-S5.Ernsberger P., Separovic D., Kester M. Imidasoline I-1-receptor as a therapeutic target in hypertension and syndrome X. Imidasoline I-1-Receptor Agonists: New Date On Hypertension and related Pathologies.- XVIII Congress of the ESC.-Abstracts.-Birmingham, August 28,1996.Ernsberger P., Separovic D., Kester M. Imidasoline I-1-receptor as a therapeutic target in hypertension and syndrome X. Imidasoline I-1-Receptor Agonists: New Date On Hypertension and related Pathologies.- XVIII Congress of the ESC.-Abstracts.-Birmingham, August 28,1996.Faulds D. Moxonidine: a review of its pharmacology , and its therapeutics use in essential hypertension. //Drugs 1992; 44: 993-1012.Faulds D. Moxonidine: a review of its pharmacology , and its therapeutics use in essential hypertension. //Drugs 1992; 44: 993-1012.Brian NC Prichard, Barrie R. Graham and Chris WI Owens. Moxonidine: a new antiadrenergic agent. // J. Hypertension 1998;17:344-350Brian NC Prichard, Barrie R. Graham and Chris WI Owens. Moxonidine: a new antiadrenergic agent. // J. Hypertension 1998;17:344-350Haenni A, Lithell H. Moxonidine improves insulin sensetivity in insulin￾resistant hypertensive. //J. Hypertension 1999; 17 (Suppl 3): S29-S35.Haenni A, Lithell H. Moxonidine improves insulin sensetivity in insulin￾resistant hypertensive. //J. Hypertension 1999; 17 (Suppl 3): S29-S35.Litthel H. Consideration in treatment of insulin - resistance and related disorders with a new sympatholytic agent.- Imidasoline 1-1- Receptor Agonists: New Date On Hypertension and related Pathologies.- XVIII Congress of the ESC.Litthel H. Consideration in treatment of insulin - resistance and related disorders with a new sympatholytic agent.- Imidasoline 1-1- Receptor Agonists: New Date On Hypertension and related Pathologies.- XVIII Congress of the ESC.Kaan CE, Bruckner R, Frohly P et al. Effects of agmatinne and moxonidine on glucose metabolism: An integrated approach towards pathophysiological mechanism in cardiovascular metabolic disorders. // J.Cardiovascular Risk Factors 1995; (5,Supll.): 19-27.Kaan CE, Bruckner R, Frohly P et al. Effects of agmatinne and moxonidine on glucose metabolism: An integrated approach towards pathophysiological mechanism in cardiovascular metabolic disorders. // J.Cardiovascular Risk Factors 1995; (5,Supll.): 19-27.Watanabe K, SeriyaM, Takasci Kameoka et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. // J. Hypertension 1999; 17:1161-1168.Watanabe K, SeriyaM, Takasci Kameoka et al. Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. // J. Hypertension 1999; 17:1161-1168.Bucolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes. // Clin.Chem. 1973; 19:476- 479.Bucolo G., David H. Quantitative determination of serum triglycerides by the use of enzymes. // Clin.Chem. 1973; 19:476- 479.Roeschlau P, Berndt E, Gruber W. Enzimatische bestimmung des desant cholesterines in serum. // Z. Klin. Chem. Klin. Biochem. 1974; 12: 226-229.Roeschlau P, Berndt E, Gruber W. Enzimatische bestimmung des desant cholesterines in serum. // Z. Klin. Chem. Klin. Biochem. 1974; 12: 226-229.Assmann G, Schriewer H, Schmitz G, Hedele E. Quantification of high density lipoprotein cholesterol by precipitation with phosphotungstic acid/ MgCk. // Clin.Chem. 1983; 29: 2025-2029.Assmann G, Schriewer H, Schmitz G, Hedele E. Quantification of high density lipoprotein cholesterol by precipitation with phosphotungstic acid/ MgCk. // Clin.Chem. 1983; 29: 2025-2029.Stems WE, Heder G, Komissarova NW. Vertahren zur Bastimmung des Angiotensin - Converting Enzymes. // Z.Med.Labor.Diagn. l985;26:232-234.Stems WE, Heder G, Komissarova NW. Vertahren zur Bastimmung des Angiotensin - Converting Enzymes. // Z.Med.Labor.Diagn. l985;26:232-234.Metelskoya V, Serolyuk A, Mamedov M, Konstantinov V, Perova N,Oganov R. Insulin resistance markers for coronary heart disease high risk subject selection. In: Advances in lipoprotein and Atherosclerosis Research, Diagnostics and Treatment. // Gustav Fischer.1997: 192-195.Metelskoya V, Serolyuk A, Mamedov M, Konstantinov V, Perova N,Oganov R. Insulin resistance markers for coronary heart disease high risk subject selection. In: Advances in lipoprotein and Atherosclerosis Research, Diagnostics and Treatment. // Gustav Fischer.1997: 192-195.Cardillo C, Nambi S, Crescence M et al. Insulin Stimulates Both Endothelin and Nitric Oxide Activity in the Human Forearm. // Circulation 1999; 100:820-825.Cardillo C, Nambi S, Crescence M et al. Insulin Stimulates Both Endothelin and Nitric Oxide Activity in the Human Forearm. // Circulation 1999; 100:820-825.Yang X, Liu Y, Edward G. et al. Endothelial Nitric Oxide Gene Knockout Mice. // J. Hypertension 1999; 34: 24-30.Yang X, Liu Y, Edward G. et al. Endothelial Nitric Oxide Gene Knockout Mice. // J. Hypertension 1999; 34: 24-30.Hayakawa H, Raij L. Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension. // J. Hypertension 1999;17:611-619.Hayakawa H, Raij L. Relationship between hypercholesterolaemia, endothelial dysfunction and hypertension. // J. Hypertension 1999;17:611-619.Opie LH. Angiotensin Converting Enzyme Inhibitors. / University of Cape Town Press 1999; 236.Opie LH. Angiotensin Converting Enzyme Inhibitors. / University of Cape Town Press 1999; 236.Mutter DN, Fischli W, Clozel J et al. Local Angiotensin II Generation in the Rat Heart./University of Cape Town Press 1999; 244-256.Mutter DN, Fischli W, Clozel J et al. Local Angiotensin II Generation in the Rat Heart./University of Cape Town Press 1999; 244-256.

The authors declare that there are no conflicts of interest present.